FimH Antagonists: Phosphate Prodrugs Improve Oral Bioavailability

Journal of Medicinal Chemistry

Volumn 59, Issue 7, 2016, Pages 3163-3182

  Kleeb, Simon ^a   Jiang, Xiaohua ^a   Frei, Priska ^a   Sigl, Anja ^a   Bezençon, Jacqueline ^a   Bamberger, Karen ^a   Schwardt, Oliver ^a   Ernst, Beat ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIMBRIA PROTEIN; MANNOSIDE; PHOSPHATE; PRODRUG;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; C3H MOUSE; CACO 2 CELL LINE; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; INTESTINE; MOUSE; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; STOMACH ACID; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; FEMALE; FIMBRIAE PROTEINS; GASTRIC ACID; HUMANS; INTESTINES; MANNOSIDES; MICE; MICE, INBRED C3H; PHOSPHATES; PHOSPHORYLATION; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84966378417     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01923     Document Type: Article

References (56)

1. Fihn, S. D. Clinical practice. Acute uncomplicated urinary tract infection in women N. Engl. J. Med. 2003, 349, 259-266 10.1056/NEJMcp030027
2. Wiles, T. J.; Kulesus, R. R.; Mulvey, M. A. Origins and virulence mechanisms of uropathogenic Escherichia coli Exp. Mol. Pathol. 2008, 85, 11-19 10.1016/j.yexmp.2008.03.007
3. Sanchez, G. V.; Master, R. N.; Karlowsky, J. A.; Bordon, J. M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010 Antimicrob. Agents Chemother. 2012, 56, 2181-2183 10.1128/AAC.06060-11
4. Hooton, T. M.; Stamm, W. E. Diagnosis and treatment of uncomplicated urinary tract infection Infect. Dis. Clin. North Am. 1997, 11, 551-581 10.1016/S0891-5520(05)70373-1
5. Svanborg, C.; Godaly, G. Bacterial virulence in urinary tract infection Infect. Dis. Clin. North Am. 1997, 11, 513-529 10.1016/S0891-5520(05)70371-8
6. Schilling, J. D.; Mulvey, M. A.; Hultgren, S. J. Structure and function of Escherichia coli type 1 pili: new insight into the pathogenesis of urinary tract infections J. Infect. Dis. 2001, 183, S36-S40 10.1086/318855
7. Capitani, G.; Eidam, O.; Glockshuber, R.; Grütter, M. G. Structural and functional insights into the assembly of type 1 pili from Escherichia coli Microbes Infect. 2006, 8, 2284-2290 10.1016/j.micinf.2006.03.013
8. Sharon, N. Carbohydrates as future anti-adhesion drugs for infectious diseases Biochim. Biophys. Acta, Gen. Subj. 2006, 1760, 527-537 10.1016/j.bbagen.2005.12.008
9. Firon, N.; Ofek, I.; Sharon, N. Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli Biochem. Biophys. Res. Commun. 1982, 105, 1426-1432 10.1016/0006-291X(82)90947-0
10. Firon, N.; Ofek, I.; Sharon, N. Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium Carbohydr. Res. 1983, 120, 235-249 10.1016/0008-6215(83)88019-7
11. Bouckaert, J.; Berglund, J.; Schembri, M.; De Genst, E.; Cools, L.; Wuhrer, M.; Hung, C.-S.; Pinkner, J.; Slättegard, R.; Zavialov, A.; Choudhury, D.; Langermann, S.; Hultgren, S. J.; Wyns, L.; Klemm, P.; Oscarson, S.; Knight, S. D.; De Greve, H. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin Mol. Microbiol. 2005, 55, 441-455 10.1111/j.1365-2958.2004.04415.x
12. Firon, N.; Ashkenazi, S.; Mirelman, D.; Ofek, I.; Sharon, N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells Infect. Immun. 1987, 55, 472-476
13. Sperling, O.; Fuchs, A.; Lindhorst, T. K. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH. Design, synthesis and binding properties of mannoside ligands Org. Biomol. Chem. 2006, 4, 3913-3922 10.1039/b610745a
14. Han, Z.; Pinkner, J. S.; Ford, B.; Obermann, R.; Nolan, W.; Wildman, S. A.; Hobbs, D.; Ellenberger, T.; Cusumano, C. K.; Hultgren, S. J.; Janetka, J. W. Structure-based drug design and optimization of mannoside bacterial FimH antagonists J. Med. Chem. 2010, 53, 4779-4792 10.1021/jm100438s
15. Klein, T.; Abgottspon, D.; Wittwer, M.; Rabbani, S.; Herold, J.; Jiang, X.; Kleeb, S.; Lüthi, C.; Scharenberg, M.; Bezençon, J.; Gubler, E.; Pang, L.; Smiesko, M.; Cutting, B.; Schwardt, O.; Ernst, B. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation J. Med. Chem. 2010, 53, 8627-8641 10.1021/jm101011y
16. Cusumano, C. K.; Pinkner, J. S.; Han, Z.; Greene, S. E.; Ford, B. A.; Crowley, J. R.; Henderson, J. P.; Janetka, J. W.; Hultgren, S. J. Treatment and prevention of urinary tract infection with orally active FimH inhibitors Sci. Transl. Med. 2011, 3, 109ra115 10.1126/scitranslmed.3003021
17. Han, Z.; Pinkner, J. S.; Ford, B.; Chorell, E.; Crowley, J. M.; Cusumano, C. K.; Campbell, S.; Henderson, J. P.; Hultgren, S. J.; Janetka, J. W. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides J. Med. Chem. 2012, 55, 3945-3959 10.1021/jm300165m
18. Pang, L.; Kleeb, S.; Lemme, K.; Rabbani, S.; Scharenberg, M.; Zalewski, A.; Schädler, F.; Schwardt, O.; Ernst, B. FimH antagonists: structure-activity and structure-property relationships for biphenyl α- d -mannopyranosides ChemMedChem 2012, 7, 1404-1422 10.1002/cmdc.201200125
19. Kleeb, S.; Pang, L.; Mayer, K.; Eris, D.; Sigl, A.; Preston, R. C.; Zihlmann, P.; Abgottspon, D.; Hutter, A.; Scharenberg, M.; Jiang, X.; Navarra, G.; Rabbani, S.; Smiesko, M.; Lüdin, N.; Jakob, R. P.; Bezençon, J.; Schwardt, O.; Maier, T.; Sharpe, T.; Ernst, B. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile J. Med. Chem. 2015, 58, 2221-2239 10.1021/jm501524q
20. Jiang, X.; Abgottspon, D.; Kleeb, S.; Rabbani, S.; Scharenberg, M.; Wittwer, M.; Haug, M.; Schwardt, O.; Ernst, B. Anti-adhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success J. Med. Chem. 2012, 55, 4700-4713 10.1021/jm300192x
21. Schwardt, O.; Rabbani, S.; Hartmann, M.; Abgottspon, D.; Wittwer, M.; Kleeb, S.; Zalewski, A.; Smiesko, M.; Cutting, B.; Ernst, B. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists Bioorg. Med. Chem. 2011, 19, 6454-6473 10.1016/j.bmc.2011.08.057
22. Brument, S.; Sivignon, A.; Dumych, T. I.; Moreau, N.; Roos, G.; Guérardel, Y.; Chalopin, T.; Deniaud, D.; Bilyy, R. O.; Darfeuille-Michaud, A.; Bouckaert, J.; Gouin, S. G. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients J. Med. Chem. 2013, 56, 5395-5406 10.1021/jm400723n
23. Lindhorst, T. K.; Kieburg, C.; Krallmann-Wenzel, U. Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary d -mannosyl clusters: The effect of multivalency Glycoconjugate J. 1998, 15, 605-613 10.1023/A:1006920027641
24. Nagahori, N.; Lee, R. T.; Nishimura, S.-L.; Pagé, S.; Roy, R.; Lee, Y. C. Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands ChemBioChem 2002, 3, 836-844 10.1002/1439-7633(20020902)3:9<836::AID-CBIC836>3.0.CO;2-2
25. Appeldoorn, C. C. M.; Joosten, J. A. F.; Ait el Maate, F. A.; Dobrindt, U.; Hacker, J.; Liskamp, R. M. J.; Khan, A. S.; Pieters, R. J. Novel multivalent mannose compounds and their inhibition of the adhesion of type 1 fimbriated uropathogenic E. coli Tetrahedron: Asymmetry 2005, 16, 361-372 10.1016/j.tetasy.2004.11.014
26. Patel, A.; Lindhorst, T. K. A modular approach for the synthesis of oligosaccharide mimetics Carbohydr. Res. 2006, 341, 1657-1668 10.1016/j.carres.2006.01.024
27. Touaibia, M.; Wellens, A.; Shiao, T. C.; Wang, Q.; Sirois, S.; Bouckaert, J.; Roy, R. Mannosylated M(0) dendrimers with nanomolar affinities to Escherichia coli FimH ChemMedChem 2007, 2, 1190-1201 10.1002/cmdc.200700063
28. Durka, M.; Buffet, K.; Iehl, J.; Holler, M.; Nierengarten, J.-F.; Taganna, J.; Bouckaert, J.; Vincent, S. P. The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH-towards novel bacterial antiadhesives Chem. Commun. 2011, 47, 1321-1323 10.1039/C0CC04468G
29. Bouckaert, J.; Li, Z.; Xavier, C.; Almant, M.; Caveliers, V.; Lahoutte, T.; Weeks, S. D.; Kovensky, J.; Gouin, S. G. Heptyl α- d -mannosides grafted on a β-cyclodextrin core to interfere with Escherichia coli adhesion: An in vivo multivalent effect Chem.-Eur. J. 2013, 19, 7847-7855 10.1002/chem.201204015
30. Scharenberg, M.; Schwardt, O.; Rabbani, S.; Ernst, B. Target selectivity of FimH antagonists J. Med. Chem. 2012, 55, 9810-9816 10.1021/jm3010338
31. Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: Optimization of drug absorption and pharmacokinetics J. Med. Chem. 2001, 44, 1313-1333 10.1021/jm000407e
32. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-420 10.1023/A:1016212804288
33. Heimbach, T.; Oh, D.-M.; Li, L. Y.; Forsberg, M.; Savolainen, J.; Leppänen, J.; Matsunaga, Y.; Flynn, G.; Fleisher, D. Absorption rate limit considerations for oral phosphate prodrugs Pharm. Res. 2003, 20, 848-856 10.1023/A:1023827017224
34. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility Adv. Drug Delivery Rev. 2007, 59, 677-694 10.1016/j.addr.2007.05.013
35. Stewart, B. H.; Amidon, G. L.; Brabec, R. K. Uptake of prodrugs by rat intestinal mucosal cells: mechanism and pharmaceutical implications J. Pharm. Sci. 1986, 75, 940-945 10.1002/jps.2600751005
36. Wire, M. B.; Shelton, M. J.; Studenberg, S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug Clin. Pharmacokinet. 2006, 45, 137-168 10.2165/00003088-200645020-00002
37. Hersh, M. R.; Kuhn, J. G.; Phillips, J. L.; Clark, G.; Ludden, T. M.; Von Hoff, D. D. Pharmacokinetic study of fludarabine phosphate (NSC 312887) Cancer Chemother. Pharmacol. 1986, 17, 277-280 10.1007/BF00256699
38. Rabbani, S.; Jiang, X. H.; Schwardt, O.; Ernst, B. Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay Anal. Biochem. 2010, 407, 188-195 10.1016/j.ab.2010.08.007
39. Alsenz, J.; Kansy, M. High throughput solubility measurement in drug discovery and development Adv. Drug Delivery Rev. 2007, 59, 546-567 10.1016/j.addr.2007.05.007
40. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248 10.1517/17460441003605098
41. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 1998, 41, 1007-1010 10.1021/jm970530e
42. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA-Critical factors for better predictions of absorption J. Pharm. Sci. 2007, 96, 2893-2909 10.1002/jps.21068
43. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175, 880-885 10.1016/0006-291X(91)91647-U
44. Hubatsch, I.; Ragnarsson, E. G. E.; Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2007, 2, 2111-2119 10.1038/nprot.2007.303
45. DeGoey, D. A.; Grampovnik, D. J.; Flosi, W. J.; Marsh, K. C.; Wang, X. C.; Klein, L. L.; McDaniel, K. F.; Liu, Y.; Long, M. A.; Kati, W. M.; Molla, A.; Kempf, D. J. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir J. Med. Chem. 2009, 52, 2964-2970 10.1021/jm900080g
46. Ma, Z.; Zhang, J.; Kong, F. Facile synthesis of arabinomannose penta- and decasaccharide fragments of the lipoarabinomannan of the equine pathogen, Rhodococcus equi Carbohydr. Res. 2004, 339, 1761-1771 10.1016/j.carres.2004.04.012
47. Dong, H.; Pei, Z.; Byström, S.; Ramström, O. Reagent-Dependent Regioselective Control in Multiple Carbohydrate Esterifications J. Org. Chem. 2007, 72, 1499-1502 10.1021/jo0620821
48. Yuan, H.; Li, N.; Lai, Y. Evaluation of in vitro models for screening phosphatase-mediated bioconversion of phosphate ester prodrugs Drug Metab. Dispos. 2009, 37, 1443-1447 10.1124/dmd.108.026245
49. Kearny, A. S.; Stella, V. J. The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs Pharm. Res. 1992, 9, 497-503 10.1023/A:1015840329786
50. Dhareshwar, S. S.; Stella, V. J. A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives J. Pharm. Sci. 2010, 99, 2711-2723 10.1002/jps.22021
51. The United States Pharmacopeia (USP 28); U. S. Pharmacopeia: Rockville, MD, 2004.
52. Dressman, J. B.; Thelen, K.; Jantratid, E. Towards quantitative prediction of oral drug absorption Clin. Pharmacokinet. 2008, 47, 655-667 10.2165/00003088-200847100-00003
53. Stephens, R. H.; O'Neill, C. A.; Warhurst, A.; Carlson, G. L.; Rowland, M.; Warhurst, G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J. Pharmacol. Exp. Ther. 2001, 296, 584-591
54. Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 2010, 99, 306-314 10.1016/j.cmpb.2010.01.007
55. Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 2008, 25, 1663-1676 10.1007/s11095-008-9569-4
56. Diehl, K.-H.; Hull, R.; Morton, D.; Pfister, R.; Rabemampianina, Y.; Smith, D.; Vidal, J.-M.; Van de Vorstenbosch, C. A good practice guide to the administration of substances and removal of blood, including routes and volumes J. Appl. Toxicol. 2001, 21, 15-23 10.1002/jat.727